We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$950M
AUM Growth
+$325M
Cap. Flow
+$425M
Cap. Flow %
44.74%
Top 10 Hldgs %
62.17%
Holding
40
New
10
Increased
8
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$187M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$84.3M
3
TVTX icon
Travere Therapeutics
TVTX
+$37M
4
HLVX
HilleVax
HLVX
+$28.7M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$27M

Top Sells

Rank Stock Value
1
GHRS icon
GH Research
GHRS
+$8.93M
2
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$7.18M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$5.65M
4
BDTX icon
Black Diamond Therapeutics
BDTX
+$1.79M
5
AVTX icon
Avalo Therapeutics
AVTX
+$444K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
26
Praxis Precision Medicines
PRAX
$8.58B
$9.07M 0.95%
353,627
– –
SLRN
27
DELISTED
ACELYRIN
SLRN
$8.79M 0.93%
+864,332
New +$18.4M
TRVI icon
28
Trevi Therapeutics
TRVI
$2.59B
$7.46M 0.79%
3,422,397
– –
ACRS icon
29
Aclaris Therapeutics
ACRS
$726M
$7.13M 0.75%
1,040,754
– –
MIST icon
30
Milestone Pharmaceuticals
MIST
$138M
$6.85M 0.72%
2,208,812
– –
PLRX icon
31
Pliant Therapeutics
PLRX
$64.4M
$5.01M 0.53%
288,949
– –
SGMT icon
32
Sagimet Biosciences
SGMT
$439M
$4.53M 0.48%
+515,000
New +$6.86M
SYRE icon
33
Spyre Therapeutics
SYRE
$8.54B
$3.61M 0.38%
295,034
+41,305
+16% +$546K
LYRA
34
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.61M 0.38%
18,483
– –
OLMA icon
35
Olema Pharmaceuticals
OLMA
$1B
$951K 0.1%
+77,042
New +$785K
RLYB icon
36
Rallybio
RLYB
$84.5M
$905K 0.1%
33,567
– –
AFMD
37
DELISTED
Affimed
AFMD
$683K 0.07%
142,857
– –
AVTX icon
38
Avalo Therapeutics
AVTX
$965M
– –
-5,208
Closed -$444K
BDTX icon
39
Black Diamond Therapeutics
BDTX
$96.8M
– –
-353,629
Closed -$1.79M
THRX
40
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-770,000
Closed -$7.18M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2023 Portfolio in Review

As of Q3 2023, VR Adviser held 40 positions worth $950M, up 52% from $625M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

VR Adviser deployed $425M of net new capital in Q3 2023, opening 10 new positions and adding to 8 existing holdings. Its largest new stake was Apogee Therapeutics: 8,493,321 shares worth $181M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was GH Research, an estimated $8.93M trimmed.

  • VR Adviser's largest Q3 2023 buy was Apogee Therapeutics: 8,493,321 shares worth $181M.
  • VR Adviser added most to Enliven Therapeutics in Q3 2023, an estimated $12.2M increase.
  • VR Adviser's biggest Q3 2023 reduction was GH Research, cutting an estimated $8.93M.
  • VR Adviser fully exited Theseus Pharmaceuticals, Inc. Common Stock in Q3 2023, selling an estimated $7.18M.
  • VR Adviser's ten largest holdings make up 62% of its $950M portfolio in Q3 2023.
  • VR Adviser opened 10 new positions and closed 3 in Q3 2023.
  • VR Adviser's portfolio value rose 52% quarter-over-quarter to $950M.

Based on VR Adviser's 13F filing for Q3 2023, filed 14 Nov 2023.